Galien Week of Innovation featuring Mayne Pharma.
Register here to join the Galien Week of Innovation's fourth Pharma panel on Tuesday, October 24, at 2PM ET, as speakers discuss whether private-sector R&D incentives are aligned to meet growing market needs, and how to address unmet needs in women’s health therapeutics: https://lnkd.in/e5dxGx7W Featuring speakers from: Gilead Sciences, Mayne Pharma, Sumitomo Pharma America, Inc., ViiV Healthcare
Mayne Pharma and Sandoz announced a partnership for Mayne Pharma to provide Sandoz exclusive rights to promote, sell and distribute Mayne Pharma® Oxycodone IR 5 mg and Metaraminol MYX® 10 mg / 1 ml Solution for Injection Ampoules 5 in Australia. General Manager for Mayne Pharma, Grant Swart, commented: “Our relationship with Sandoz is aligned to our longer-term growth strategy where we will look to establish mutually beneficial relationships with our partners. Oxycodone and Metaraminol are both well-established products in the Australian market and this new agreement will ensure increased availability for patients. We look forward to a successful long-term partnership with Sandoz to provide greater access to medicines for patients.”
We’re #hiring a new Women's Health Specialist in Sacramento, California. Apply today!
